At Veravas we’re passionate about improving the quality of biomarker measurement – both what is being measured in patient samples and the accuracy of results. Through this, we hope to establish a new gold standard for laboratory testing where every result is correct the first time, every time.
In real terms, we’re targeting two key issues within our field. The first is the widespread issue of diagnostic interferences – substances like biotin that alter routine test results. The second is the difficulty in measuring biomarkers of low abundance. With our patent-pending technology, we are moving the needle on what is possible to measure, realizing the potential of low abundance biomarkers to better diagnose and treat rare and common diseases.
To make the most of these advances, we’re developing a portfolio of tests, while also providing a platform for companies to advance their novel assays. With this approach, we believe we can make the biggest impact in the shortest amount of time.
The Veravas team is transforming the practice of laboratory medicine, delivering diagnostics that are accurate, accessible, and affordable.
Chief Executive Officer
Carroll is a seasoned executive with over 30 years focused on diagnostics. He served as president of a large in vitro diagnostics medical device/assay manufacturing company, DiaSorin, and has held several executive level positions with other diagnostic companies, as well as in hospital services, managed care providers, and home health companies. Carroll brings a deep level of international business development, licensing and contracting, and distribution channel development experience to the company.
Founder & Chief Revenue Officer
John is an entrepreneur with 30 years of experience in global healthcare IT and innovation. Throughout his dynamic career, he has worked to create companies and advance technologies that give patients easier access to quality healthcare testing and information. Addressing current issues in laboratory medicine is a critical step towards improving the human condition.
Chief Medical Officer
Carmen is a board certified, Mayo Clinic-trained clinical chemist. She is a former scientific director of a U.S. national reference lab and current president of the American Association of Clinical Chemistry (AACC) – a global scientific and medical professional organization dedicated to better health through laboratory medicine. Carmen also brings experience gleaned from senior scientific roles at Roche and PAML.
Chief Scientific Officer
Josh is an innovative leader and proven global scientific affairs executive in diagnostics and life sciences. He is a subject matter expert in assay development and solid-phase chemistry with multiple patents and publications. He was formerly at Roche, DiaSorin, and Beckman Coulter.
Chief Financial Officer
Fred brings 40 years of financial and investment leadership to his role as CFO. He has worked with over 30 medical device and tech startup companies and is a founding partner of TechCXO, a management consulting firm that provides growth-stage companies with CFO, CTO, CMO, and CSO support.
Do you have the skills and the passion to move diagnostics and precision medicine forward? Learn more about career opportunities at Veravas.
Invest in Veravas; grow as we grow. Reach out to John Forrest to learn more about our business vision, milestones, and investment opportunities.